Vanda Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 203

Market Cap: $311.8M

Website

Introduction: Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Clinical Trials

A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: Iloperidone

First Posted Date: 2021-01-15

Last Posted Date: 2023-06-29

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 42

Registration Number: NCT04712734

Locations: 🇺🇸
Vanda Investigational Site, Marlton, New Jersey, United States

Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)

Phase 3

Recruiting

Conditions: Sleep Disorders, Circadian Rhythm
Chronobiology Disorders
Sleep Wake Disorders

Interventions: Drug: Tasimelteon
Drug: Placebo

First Posted Date: 2020-12-03

Last Posted Date: 2024-11-19

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 70

Registration Number: NCT04652882

Locations: 🇩🇪
Vanda Investigational Site, Schwerin, Germany

Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies

Phase 2

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: VSJ-110
Drug: Placebo

First Posted Date: 2020-11-09

Last Posted Date: 2022-04-27

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 41

Registration Number: NCT04622345

Locations: 🇺🇸
Vanda Investigational Site, Andover, Massachusetts, United States

Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis

Conditions: Gastroparesis
Diabetic Gastroparesis

First Posted Date: 2020-07-17

Last Posted Date: 2023-10-04

Lead Sponsor: Vanda Pharmaceuticals

Registration Number: NCT04474990

Locations: 🇺🇸
Vanda Investigational Site, Spokane, Washington, United States

WGS Analysis of COVID-19 Positive Patients

Completed

Conditions: COVID-19
Coronavirus Infection

First Posted Date: 2020-04-20

Last Posted Date: 2024-03-22

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 79

Registration Number: NCT04353401

Locations: 🇺🇸
Vanda Investigational Site, Cleveland, Ohio, United States

Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

Phase 3

Completed

Conditions: Motion Sickness

Interventions: Drug: Tradipitant
Drug: Placebo

First Posted Date: 2020-03-31

Last Posted Date: 2024-12-11

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 366

Registration Number: NCT04327661

Locations: 🇺🇸
Gulfcoast Psychiatric Associates, Fort Myers, Florida, United States
🇺🇸
Pacific Research Network, LLC, San Diego, California, United States
🇺🇸
Santa Monica Clinical Trials, Santa Monica, California, United States

and more 4 locations